Jacob Plieth

Remember the time a young Ben Bradlee broke the story about J Edgar Hoover being replaced, and the next day Lyndon Johnson appointed Hoover head of the FBI for life?

@raffcolo Maybe it was something I tweeted.

@JacobPlieth they resumed publishing several new ones open.fda.gov/crltable/

Anyone care to out the unnamed pharma company whose citizen's petition has apparently resulted in the FDA pausing the release of further CRLs?

Meanwhile, Chinese ph3 study of MHB088C does mandate prior PD-L1

Bizarre find of the day: $DSNKY $MRK Ideate-Lung2 study of ifinatamab-dxd in 2L SCLC also mandates only for failure on platinum chemo, not on prior PD-L1 #participation-criteria" target="_blank" rel="nofollow noopener">clinicaltrials.gov/study/NCT06203…

Amazing, given the design of Artemis-008 and its virtual irrelevance to western SoC, that $GSK even bothered to press release this otp.tools.investis.com/generic/regula…

$URGN parking its tanks on $CGON's lawn here. Though what they don't tell you is that this is the Iconovir asset FKA ICVB-1042 that already failed in phase 1 investors.urogen.com/news-releases/…

@PearlF Ah, good connection!

GSK alum Robin Carr co-founded London-based Myricx & joined as Chief Development Officer in '19 & is CTO currently. ex Exscientia EVP Medical Chemistry Andy Bell is a co-founder. Boston-based CEO Mohit Rawat is ex VP at $NVS Oncology

@gelantonia Indeed! I don't think Myricx has ever run a clinical trial. $NVS

@JacobPlieth Is that 1.1 billion based on pre clinical data only Jacob? I like the move to more novel Approaches away from the crowd.its a risk but a better risk than joining the herd and burning cash going nowhere. Innovation prevails 👍

Myricx Bio's secret sauce: an N-myristoyltransferase inhibitor (NMTi) ADC payload, from Robin Carr poster at #WorldADC23. Just acquired by $NVS for $ 1.1bn.

Side note: Pacylex Pharmaceuticals (Canada) seems to be the only company developing an NMT inhibitor as a drug in its own right: zelenirstat, in ph2 for DLBCL

Another ADC acquisition. This time novel payload (N-Myristoyltransferase inhibitor) $NVS to acquire Myricx (UK based) for $1.1B u/f + $0.4B backend. Seeded by Sofinnova Partners (Maina Bhaman) and Brandon Capital (Jonathan Tobin). Series A co-led by Abingworth (Jayson Punwani) and Novo Holdings (Michael Bauer) $114m series A was exactly 2 years ago. So this must be a very good return. businesswire.com/news/home/2026…

Still, amazing that Orca has succeeded where Molmed, Kiadis & $BLCM failed

Is "allogeneic regulatory T cell-based immunotherapy with HSPC and T cells-vldq" the INN? Wow

Some background on $IPSEY Kartos, from last year apexonco.com/node/1249 $PMVP

Whichever smartalec ibanker pitched this deal to $ZYME, I salute you ir.zymeworks.com/news-releases/…

Ipsen doesn't buy $PMVP ipsen.com/press-release/…

Rezatopopt sees a path forward after all, but $PMVP sells off 10%. Via @ApexOnco -> oncologypipeline.com/apexonco/node/…

That one is especially curious since $MRNA hasn't disclosed the antigens targeted by mRNA-4106 or mRNA-4200. Does mRNA-4200 have anything to do with Lag3? $MRK $BMY

$MRNA initially planned to test mRNA-4106 as monoRx, or mRNA-4106 + Opdualag combo. Now it's mRNA-4106 monoRx, or mRNA-4200 +/- Keytruda

Some curious clinical trial design changes slipped out in the past few days by Zumutor / $CHRS & $MRNA

$CHRS announced a clinical-trial collab on 23 Jun, and that's apparently slotted into Zumutor's existing IND. Did Zumutor fail to sign a clinical-trial collab with $MRK?

Zumutor initially was to test ZM008 + Keytruda, but now it's ZM008 + Loqtorzi $CHRS